MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:53:30 2024-07-12 pm EDT | ||
| 15.93 EUR | -1.85% |
|
| Current month | +9.79% | ||
| 1 month | +5.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 15.93 | -1.85% |
| 24-07-11 | 16.23 | +0.31% |
| 24-07-10 | 16.18 | +2.41% |
| 24-07-09 | 15.8 | +2.20% |
| 24-07-08 | 15.46 | +5.67% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 03:53 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB71WP |
| ISIN | DE000MB71WP1 |
| Date issued | 2023-06-06 |
| Strike | 315.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.36 € |
|---|---|
| Lowest since issue | 3.8 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
488.7
USD
Average target price
473.1
USD
Spread / Average Target
-3.20%
- Stock Market
- Certificates
- Certificat
